While these findings suggest FSTL1 as a promising biomarker for disease progression and therapeutic response, further studies are warranted to validate its clinical utility and explore its role in OSA-related cardiometabolic complications. Here, FSTL1 is linked to obstructive sleep apnea syndrome.